Aurinia Pharmaceuticals (DB:IKAP) - Hisse Senedi Fiyatı, Haberler ve Analizler

IKAP Stoklara Genel Bakış

Ticari aşamada bir biyofarmasötik şirketi olan Aurinia Pharmaceuticals Inc., Amerika Birleşik Devletleri'nde karşılanmamış tıbbi ihtiyacı olan çeşitli hastalıkları tedavi etmek için tedaviler geliştirmeye ve ticarileştirmeye odaklanmaktadır. Daha fazla detay

IKAP temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 75.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 52.43% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 10.1% oranında arttı

Risk Analizi

Risk kontrollerimizden IKAP için herhangi bir risk tespit edilmedi.

Aurinia Pharmaceuticals Inc. Rakipler

Formycon

XTRA:FYB

€848.4m

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€102.1m

2invest

XTRA:2INV

€62.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Aurinia Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$8.34
52 Haftanın En Yüksek Seviyesi	US$8.57
52 Haftanın En Düşük Seviyesi	US$4.36
Beta	1.46
11 Aylık Değişim	31.61%
3 Aylık Değişim	41.42%
1 Yıllık Değişim	2.00%
33 Yıllık Değişim	-53.06%
5 Yıllık Değişim	15.89%
Halka arzdan bu yana değişim	35.67%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	IKAP	DE Biotechs	DE Pazar
7D	7.7%	-0.2%	0.8%
1Y	2.0%	-16.9%	9.1%

Getiri vs. Endüstri: IKAP geçen yıl % -16.9 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: IKAP geçen yıl % 9.1 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IKAP's price volatile compared to industry and market?
IKAP volatility
IKAP Average Weekly Movement	6.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: IKAP son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: IKAP 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1993	300	Peter Greenleaf	www.auriniapharma.com

Aurinia Pharmaceuticals Inc. Temel Bilgiler Özeti

Aurinia Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IKAP temel i̇stati̇sti̇kler
Piyasa değeri	€1.21b
Kazançlar(TTM)	-€21.49m
Gelir(TTM)	€209.96m

5.7x

P/S Oranı

-55.3x

F/K Oranı

IKAP aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IKAP gelir tablosu (TTM)
Gelir	US$220.36m
Gelir Maliyeti	US$51.00m
Brüt Kâr	US$169.36m
Diğer Giderler	US$191.92m
Kazançlar	-US$22.55m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.16
Brüt Marj	76.86%
Net Kâr Marjı	-10.23%
Borç/Özkaynak Oranı	0%

IKAP uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IKAP Stoklara Genel Bakış

Ödüller

Risk Analizi

Aurinia Pharmaceuticals Inc. Rakipler

XTRA:FYB

€848.4m

XTRA:BIO3

€1.4b

XTRA:HPHA

€102.1m

XTRA:2INV

€62.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released: EPS: US$0.10 (vs US$0.094 loss in 3Q 2023)

Aurinia Pharmaceuticals Inc. Announces Board Changes

Aurinia Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Aurinia Pharmaceuticals Inc. Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Aurinia Pharmaceuticals Inc. Announces Board Restructuring

Aurinia Pharmaceuticals Inc Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Recent updates

Third quarter 2024 earnings released: EPS: US$0.10 (vs US$0.094 loss in 3Q 2023)

Aurinia Pharmaceuticals Inc. Announces Board Changes

Aurinia Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Aurinia Pharmaceuticals Inc. Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Aurinia Pharmaceuticals Inc. Announces Board Restructuring

Aurinia Pharmaceuticals Inc Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Lucien Selce Sends Letter to the Board of Directors of Aurinia Pharmaceuticals

Second quarter 2024 earnings released: EPS: US$0.005 (vs US$0.08 loss in 2Q 2023)

Aurinia Pharmaceuticals Inc. Revises Net Product Revenue Guidance for the Fiscal Year 2024

Aurinia Pharmaceuticals Inc. Revises Net Product Revenue Guidance for the Fiscal Year 2024

Aurinia Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 01, 2024

ILJIN SNT Co Provides Information to Shareholders of Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis

Lucien Selce Sends Letter to Aurinia shareholders

Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024

Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value

Forecast breakeven date moved forward to 2024

Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

First quarter 2024 earnings released: US$0.075 loss per share (vs US$0.18 loss in 1Q 2023)

Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program

Aurinia Pharmaceuticals Inc. to Report Q1, 2024 Results on May 02, 2024

Aurinia Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals

President recently sold €652k worth of stock

Forecast breakeven date moved forward to 2024

Full year 2023 earnings released: US$0.55 loss per share (vs US$0.76 loss in FY 2022)

Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH) announces an Equity Buyback for $150 million worth of its shares.

Aurinia Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 15, 2024

Aurinia Pharmaceuticals Inc. Submits IND Application to US Food & Drug Administration for AUR 200

Aurinia Pharmaceuticals Inc. Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS for Managing Lupus Nephritis

Third quarter 2023 earnings released: US$0.094 loss per share (vs US$0.063 loss in 3Q 2022)

Aurinia Pharmaceuticals Inc. Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

Aurinia Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 02, 2023

Less than half of directors are independent

Aurinia Pharmaceuticals Appoints Robert T. Foster to its Board

Aurinia Pharmaceuticals Inc. Announces Board Changes

Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2023

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.08 loss per share (vs US$0.25 loss in 2Q 2022)

Aurinia Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 03, 2023

Aurinia Pharmaceuticals Inc. Announces Full Results from the Phase 3, Double-Blind, Placebo-Controlled Aurora 2 Extension Study

New minor risk - Insider selling

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

Aurinia Pharmaceuticals Inc. Announces the Results of A Post-Hoc, Pooled Analysis of the Phase 2 Aura-Lv and Phase 3 Aurora 1 Studies

Now 26% undervalued

Independent Director recently sold €50k worth of stock

MKT Capital Plans to Withhold Support for the Majority of the Board

Aurinia Pharmaceuticals Inc. Announces Kidney Biopsies Sub-Study Data from the LUPKYNIS (voclosporin) AURORA 2 Clinical Trial

Now 21% undervalued

Forecast to breakeven in 2025

MKT Capital Files an Exempt Solicitation Statement and Urge Support for its Proposal

Aurinia Pharmaceuticals Inc. Provides Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.27 loss in 1Q 2022)

Aurinia Pharmaceuticals Announces National Institute for Health and Care Excellence Recommendation of LUPKYNIS® (Voclosporin) for Adults with Active Lupus Nephritis

Independent Chairman of the Board recently bought €168k worth of stock

Full year 2022 earnings released: US$0.76 loss per share (vs US$1.40 loss in FY 2021)

Aurinia Pharmaceuticals Inc. to Report Q4, 2022 Results on Feb 28, 2023

Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for 2023

Insufficient new directors